drugset / Trial / NCT03412682

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

NCT03412682

Phase 3 Completed 274 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.

Timeline

Start
2018-03-02
Primary completion
2020-05-11
Completion
2020-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 6 mg
Subject Budesonide Small molecule 9 mg
Comparator Mesalamine Small molecule 400 mg
Comparator Mesalamine Small molecule 3600 mg

Indications